ISSN 2407-2230 | E-ISSN 1907-3062 | Universa Medicina content is searchable on DOAJ, Google Scholar, and OAI

IFNG Polymorphism (+874 T>A) is not a risk factor for cervical cancer

Ani Melani Maskoen, Herman Susanto, Samsudin Surialaga, Edhyana Sahiratmadja
Submission date: Wednesday, 02 December 2015
Published date: Monday, 14 December 2015


INTRODUCTION Cervical cancer cases are rising and many women are infected with human papillomavirus (HPV). Interferon gamma (IFN-ã) is one of the key regulatory cytokines that influence the HPV clearance. The production and the function of IFN-ã may impaired by the defect of the IFNG gene leading to the cervical malignant progression. This study aimed to examine the association between IFNG+874 T>A polymorphism and cervical cancer in women METHODS In a case-control study design, consecutive untreated women with cervical cancer who showed for the first time in Hasan Sadikin Hospital Bandung were enrolled (n=98) and for controls women who came for PAP smear (n = 81). Controls were not matched in ages and ethnicities. DNA extracted from blood was amplified by amplification refractory mutation system - polymerase chain reaction method (ARMS – PCR) to detect IFNG+874 T>A polymorphism. RESULTS The distribution of IFNG genotypes TT, TA and AA for women with cervical cancer who met the inclusion criteria (n= 64) and with negative intraepithelial lesion or malignancy (n=42) were 14.1%, 50.0%, 35.9% and 7.1%, 52.4%, 40.5%, respectively. No significant differences could be observed between both groups (p=0.64). Stratifying the cervical cancer women into a group of squamous cell carcinoma (n = 54) revealed no statistical different. CONCLUSION IFNG +874 T>A polymorphismseems not to contribute in susceptibility to cervical cancer. Identification of other variants in IFNG gene signaling and its role in the development of cervical cancer diseases need to be further examined.


IFNG gene; single nucleotide polymorphism; cervical cancer

Full Text:



Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008;110 Suppl 2:S4-7.

Aziz MF. Gynecological cancer in Indonesia. J Gynecol Oncol 2009;20:8-10.

Coutlée F, Ratnam S, Ramanakumar AV, Insinga RR, Bentley J, Escott N, et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol 2011; 83:1034-41.

Stanley M. HPV-immune response to infection and vaccination. Infect Agent Cancer 2010;20:19.

Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010;202:1789-99.

Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol 2010;118 Suppl 1:S12-7.

van de Vosse E, Ottenhoff TH. Human host genetic factors in mycobacterial and Salmonella infection: lessons from single gene disorders in IL-12/IL-23-dependent signaling that affect innate and adaptive immunity. Microbes Infect 2006;8:


Gangwar R, Pandey S, Mittal RD. Association of interferon-gamma +874A polymorphism with the risk of developing cervical cancer in a North Indian population. BJOG 2009;116:1671-7.

Song SH, Lee JK, Lee NW, Saw HS, Kang JS, Lee KW. Interferon-gamma (IFN-gamma): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV). Gynecol Oncol 2008;108: 543–8.

Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, et al.Host genetic polymorphism analysis in cervical cancer. Clin Chem 2002;48:1218-24.

Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum

Immunol 2000;61:863–6.

Hoffmann SC, Stanely EM, Cox ED, Di Mercurio BS, Koziol DE, Harlan DM. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Trans 2002;2:560-7.

Govan VA, Carrara HR, Sachs JA, Hoffman M, Stanczuk GA, Williamson AL. Ethnic differences in allelic distribution of IFN-ã in South African women but no link with cervical cancer. J Carcinog


Amim LH, Pacheco AG, Fonseca-Costa J, Loredo CS, Rabahi MF, Melo MH, et al. Role of IFNgamma +874 T/A single nucleotide polymorphism in the tuberculosis outcome among Brazilians

subjects. Mol Biol Rep 2008;35:563-6.

Mi YY, Yu QQ, Xu B, Zhang LF, Min ZC, Hua LX, et al. interferon gamma +874 T/a polymorphism contributes to cancer susceptibility: a meta- analysis based on 17 case-control studies. Mol Biol Rep 2011;38:4461-7.

von Linsingen R, Bompeixe EP, Maestri CA, Carvalho NS, da Graça BM. IFNG (+874 T/ A) polymorphism and cervical intraepithelial neoplasia in Brazilian women. J Interferon

Cytokine Res 2009;29:285-8.

Sjoeborg KD, Tropé A, Lie AK, Jonassen CM, Steinbakk M, Hansen M, et al. HPV genotype distribution according to severity of cervical neoplasia. Gynecol Oncol 2010;118:29-34.

Gey A, Kumari P, Sambandam A, Lecuru F, Cassard L, Badoual C, et al. Identification and characterization of a group of cervical carcinoma patients with profound down- regulation of

intratumoral type 1 (IFN gamma) and type 2 (IL-4) cytokine mRNA expression. Eur J Cancer 2003;39: 595–603.

Kordi TMK, Sobti RC, Shekari M, Mukesh M, Suri V. Expression and polymorphism of IFNgamma

gene in patients with cervical cancer. Exp Oncol 2008;30:224–9.

El-Sherif AM, Seth R, Tighe PJ, Jenkins D. Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer. J Pathol 2001;195:179-85.

Farzaneh F, Roberts S, Mandal D, Ollier B, Winters U, Kitchener HC, et al. The IL-10 -1082G

polymorphism is associated with clearance of HPV

infection. BJOG 2006;113:961–4.

Stanczuk GA, Sibanda EN, Perrey C, Chirara M,

Pravica V, Hutchinson IV, et al.Cancer of the

uterine cervix may be significantly associated with

a gene polymorphism coding for increased IL-10

production. Int J Cancer 2001;94:792-4.

Kim JW, Roh JW, Park NH, Song YS, Kang SB,

Lee HP. Interferon, alpha (IFN17) Ile184Arg

polymorphism and cervical cancer risk. Cancer Lett 2003;189:183-8.

Agorastos T, Lambropoulos AF, Constantinidis TC, Kotsis A, Bontis JN. p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women. Eur J Cancer Prev 2000;9:113-8.

Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet

Oncol 2009;10:772-84.


  • There are currently no refbacks.

Copyright (c) 2015 Universa Medicina

Creative Commons License
Universa Medicina by Faculty of Medicine, Trisakti University is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Based on a work at